ArticleJournal for immunotherapy of cancer2025

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

Rebecca Porter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.